A PYMNTS Company

UK/ US: Drugmaker Shire bids $30 billion for Baxalta

By  |  August 4, 2015

Drug maker Shire said on Tuesday it was seeking to buy Baxalta (BXLT.N), a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The London-listed group went public with its approach after the U.S. firm turned it down during private talks last month.

    Baxalta rebuffed the offer on Tuesday and said in a statement that Shire’s unsolicited offer significantly undervalued the company.

    Full content: The New York Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.